145 related articles for article (PubMed ID: 36716382)
1. Evaluating treatment response to mepolizumab in patients with severe CRSwNP.
Hopkins C; Han JK; Lund VJ; Bachert C; Fokkens WJ; Diamant Z; Mullol J; Sousa AR; Smith SG; Yang S; Mayer B; Yancey SW; Chan RH; Lee SE
Rhinology; 2023 Apr; 61(2):108-117. PubMed ID: 36716382
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
Fokkens W; Trigg A; Lee SE; Chan RH; Diamant Z; Hopkins C; Howarth P; Lund V; Mayer B; Sousa AR; Yancey S; Tabberer M;
J Patient Rep Outcomes; 2023 Jan; 7(1):4. PubMed ID: 36662344
[TBL] [Abstract][Full Text] [Related]
3. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.
Desrosiers M; Diamant Z; Castelnuovo P; Hellings PW; Han JK; Peters AT; Silver J; Smith SG; Fuller A; Sousa AR; Chan RH; Gevaert P;
Int Forum Allergy Rhinol; 2024 Jan; 14(1):18-31. PubMed ID: 37345861
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps.
Chupp G; Alobid I; Lugogo NL; Kariyawasam HH; Bourdin A; Chaker AM; Smith SG; Sousa AR; Mayer B; Chan RH; Matucci A
J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3504-3512.e2. PubMed ID: 37586475
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis.
Fokkens WJ; Mullol J; Kennedy D; Philpott C; Seccia V; Kern RC; Coste A; Sousa AR; Howarth PH; Benson VS; Mayer B; Yancey SW; Chan R; Gane SB
Allergy; 2023 Mar; 78(3):812-821. PubMed ID: 35822924
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Han JK; Bachert C; Fokkens W; Desrosiers M; Wagenmann M; Lee SE; Smith SG; Martin N; Mayer B; Yancey SW; Sousa AR; Chan R; Hopkins C;
Lancet Respir Med; 2021 Oct; 9(10):1141-1153. PubMed ID: 33872587
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
Bachert C; Sousa AR; Han JK; Schlosser RJ; Sowerby LJ; Hopkins C; Maspero JF; Smith SG; Kante O; Karidi-Andrioti DE; Mayer B; Chan RH; Yancey SW; Chaker AM
J Allergy Clin Immunol; 2022 May; 149(5):1711-1721.e6. PubMed ID: 35007624
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.
Mullol J; Lund VJ; Wagenmann M; Han JK; Sousa AN; Smith SG; Mayer B; Chan RH; Fokkens WJ
Rhinology; 2024 Jun; 62(3):320-329. PubMed ID: 38217844
[TBL] [Abstract][Full Text] [Related]
10. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
[TBL] [Abstract][Full Text] [Related]
11. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD013513. PubMed ID: 32102112
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V
J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP.
Desrosiers M; Mannent LP; Amin N; Canonica GW; Hellings PW; Gevaert P; Mullol J; Lee SE; Fujieda S; Han JK; Hopkins C; Fokkens W; Jankowski R; Cho SH; Mao X; Zhang M; Rice MS; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Bachert C
Rhinology; 2021 Jun; 59(3):301-311. PubMed ID: 33847325
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care.
Galletti C; Ciodaro F; Barbieri MA; Gambino F; Ferrisi MG; Portelli D; Catalano N; Spina E; Freni F; Galletti B
Am J Otolaryngol; 2024; 45(4):104329. PubMed ID: 38696895
[TBL] [Abstract][Full Text] [Related]
16. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
Tversky J; Lane AP; Azar A
Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
[TBL] [Abstract][Full Text] [Related]
17. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
[TBL] [Abstract][Full Text] [Related]
18. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial.
Bachert C; Sousa AR; Lund VJ; Scadding GK; Gevaert P; Nasser S; Durham SR; Cornet ME; Kariyawasam HH; Gilbert J; Austin D; Maxwell AC; Marshall RP; Fokkens WJ
J Allergy Clin Immunol; 2017 Oct; 140(4):1024-1031.e14. PubMed ID: 28687232
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
